A Phase III open-label randomized study to compare the efficacy of lenalidomide–rituximab with bendamustine– rituximab in treatment-naïve follicular lymphoma
Open Access
- 4 January 2024
- journal article
- research article
- Published by Medknow in Indian Journal of Cancer
- Vol. 60 (4) , 501-504
Abstract
Introduction: Bendamustine–rituximab (BR) is the preferred regimen for the treatment of naïve follicular lymphoma (FL). Recently, lenalidomide–rituximab (LR), a chemotherapy-free protocol, has shown a good response rate in advanced FL. These regimens have never been compared in a randomized controlled trial for treatment-naïve FL in Indian patients. Materials and Methods: This Phase III open-label randomized controlled trial was conducted to compare the efficacy and safety of BR and LR. Treatment-naïve patients older than 18 years of age, ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤2, who were diagnosed with FL (Stages II–IV) were included in this study. Patients were randomized in a 1:1 ratio to receive six cycles of BR (bendamustine 90 mg/m2 Days 1–2 and rituximab 375 mg/m2 Day 1) every 4 weeks or LR (lenalidomide 20 mg Days 1–21 and rituximab 375 mg/m2) every 4 weeks. The primary end point was complete response (CR) and secondary end points were overall response rate (ORR) and toxicity. Result: We enrolled 40 patients, 20 in each group with a median age of 53 years. The CR rate was 60% and 20% in BR and LR arms, respectively (P = 0.01); however, the ORR was 88.8% and 87.3% in BR and LR arms, respectively (P = 1.0). Anemia (35% versus 10%), skin rash (35% versus 30%), diarrhea (30% versus 10%), vomiting (20% versus 10%), nephrotoxicity (15% versus 0%), and transaminitis (10% versus 0%) were more in LR than in BR, and thrombocytopenia was higher in the BR than in the LR group but statistically not different. All grade toxicities were seen in 90% and 45% in LR and BR, respectively (P = 0.05), but there was no significant difference in Grade 3 or 4 toxicity between the BR and the LR regimens (20% versus 25%). Conclusion: The ORR was similar in both the arms; however, the CR rate was significantly higher in the BR arm. BR was better tolerated than LR. (CTRI/2016/05/006904).Keywords
This publication has 12 references indexed in Scilit:
- Rituximab plus Lenalidomide in Advanced Untreated Follicular LymphomaNew England Journal of Medicine, 2018
- Profile of non-Hodgkin lymphoma: An Indian perspectiveSouth Asian Journal of Cancer, 2018
- Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin LymphomaJournal of Clinical Oncology, 2015
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialThe Lancet Oncology, 2014
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studyBlood, 2014
- R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana LinfomiJournal of Clinical Oncology, 2013
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2009
- CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood, 2005